Advances in ischemic stroke treatment: neuroprotective and combination therapies

Bibliography

• INGALL T: Stroke – incidence, mortality, morbidity and risk. J. Insur. Med. (2004) 36(2):143-152.
   PubMedGoogle Scholar
• LAPCHAK PA: Hemorrhagic transformation following ischemic stroke: significance, causes, and relationship to therapy and treatment. Curr. Neurol. Neurosci. Rep. (2002) 2(1):38-43.
   PubMedGoogle Scholar
• LYDEN PD, ZIVIN JA: Hemorrhagic transformation after cerebral ischemia: mechanisms and incidence. Cerebrovasc. Brain Metab. Rev. (1993) 5(1):1-16.
   PubMedGoogle Scholar
• MICHEL P, BOGOUSSLAVSKY J: Penumbra is brain: no excuse not to perfuse. Ann. Neurol. (2005) 58(5):661-663.
   PubMed Web of Science ®Google Scholar
• MOUSTAFA RR, BARON JC: Imaging the penumbra in acute stroke. Curr. Atheroscler. Rep. (2006) 8(4):281-289.
   PubMedGoogle Scholar
• FISHER M: The ischemic penumbra: identification, evolution and treatment concepts. Cerebrovasc. Dis. (2004) 17:1-6.
   PubMed Web of Science ®Google Scholar
• Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N. Engl. J. Med. (1995) 333(24):1581-1587.
   PubMed Web of Science ®Google Scholar
• ALBERS GW, BATES VE, CLARK WM, BELL R, VERRO P, HAMILTON SA: Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study. JAMA (2000) 283(9):1145-1150.
   PubMed Web of Science ®Google Scholar
• ALBERTS MJ: tPA in acute ischemic stroke: United States experience and issues for the future. Neurology (1998) 51(3 Suppl. 3):S53-S55.
   PubMed Web of Science ®Google Scholar
• LAPCHAK PA: Development of thrombolytic therapy for stroke: a perspective. Expert Opin. Investig. Drugs (2002) 11(11):1623-1632.
   PubMed Web of Science ®Google Scholar
• BRODERICK JP, LU M, KOTHARI R at al.: Finding the most powerful measures of the effectiveness of tissue plasminogen activator in the NINDS tPA stroke trial. Stroke (2000) 31(10):2335-2341.
   PubMed Web of Science ®Google Scholar
• CHRISTOU I, ALEXANDROV AV, BURGIN WS et al.: Timing of recanalization after tissue plasminogen activator therapy determined by transcranial doppler correlates with clinical recovery from ischemic stroke. Stroke (2000) 31(8):1812-1816.
   PubMed Web of Science ®Google Scholar
• GROTTA JC, BURGIN WS, EL-MITWALLI A et al.: Intravenous tissue-type plasminogen activator therapy for ischemic stroke: Houston experience 1996 to 2000. Arch. Neurol. (2001) 58(12):2009-2013.
   PubMed Web of Science ®Google Scholar
• RIBO M, MOLINA CA, ROVIRA A et al.: Safety and efficacy of intravenous tissue plasminogen activator stroke treatment in the 3- to 6-hour window using multimodal transcranial Doppler/MRI selection protocol. Stroke (2005) 36(3):602-606.
   PubMed Web of Science ®Google Scholar
• RUBIERA M, ALVAREZ-SABIN J, RIBO M et al.: Predictors of early arterial reocclusion after tissue plasminogen activator-induced recanalization in acute ischemic stroke. Stroke (2005) 36(7):1452-1456.
   PubMed Web of Science ®Google Scholar
• SUGG RM, PARY JK, UCHINO K et al.: Argatroban tPA stroke study: study design and results in the first treated cohort. Arch. Neurol. (2006) 63(8):1057-1062.
   PubMed Web of Science ®Google Scholar
• UCHINO K, ALEXANDROV AV, GARAMI Z, EL-MITWALLI A, MORGENSTERN LB, GROTTA JC: Safety and feasibility of a lower dose intravenous TPA therapy for ischemic stroke beyond the first three hours. Cerebrovasc. Dis. (2005) 19(4):260-266.
   PubMed Web of Science ®Google Scholar
• SCHELLINGER PD, FIEBACH JB, MOHR A, RINGLEB PA, JANSEN O, HACKE W: Thrombolytic therapy for ischemic stroke-a review. Part II – intra-arterial thrombolysis, vertebrobasilar stroke, Phase IV trials, and stroke imaging. Crit. Care Med. (2001) 29(9):1819-1825.
   PubMed Web of Science ®Google Scholar
• SCHELLINGER PD, FIEBACH JB, MOHR A, RINGLEB PA, JANSEN O, HACKE W: Thrombolytic therapy for ischemic stroke – a review. Part I – intravenous thrombolysis. Crit. Care Med. (2001) 29(9):1812-1818.
   PubMed Web of Science ®Google Scholar
• VERSTRAETE M: Newer thrombolytic agents. Ann. Acad. Med. Singapore (1999) 28(3):424-433.
   PubMedGoogle Scholar
• MULTICENTRE ACUTE STROKETRIAL-ITALY (MAST-I) GROUP: Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke. Lancet (1995) 346(8989):1509-1514.
   PubMed Web of Science ®Google Scholar
• THE MULTICENTER ACUTESTROKE TRIAL-EUROPE STUDY GROUP: Thrombolytic therapy with streptokinase in acute ischemic stroke. N. Engl. J. Med. (1996) 335(3):145-150.
   PubMed Web of Science ®Google Scholar
• ALBERS GW, CLARK WM, MADDEN KP, HAMILTON SA: ATLANTIS trial: results for patients treated within 3 hours of stroke onset. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. Stroke (2002) 33(2):493-495.
   PubMed Web of Science ®Google Scholar
• ANGEJA BG, ALEXANDER JH, CHIN R et al.: Safety of the weight-adjusted dosing regimen of tenecteplase in the ASSENT-Trial. Am. J. Cardiol. (2001) 88(11):1240-1245.
   PubMed Web of Science ®Google Scholar
• BENEDICT CR, REFINO CJ, KEYT BA et al.: New variant of human tissue plasminogen activator (TPA) with enhanced efficacy and lower incidence of bleeding compared with recombinant human TPA. Circulation (1995) 92(10):3032-3040.
   PubMed Web of Science ®Google Scholar
• HAROLD P. ADAMS JR, THOMAS G et al.: Guidelines for thrombolytic therapy for acute stroke: a supplement to the guidelines for the management of patients with acute ischemic stroke. Circulation (1996) 94:1167-1174.
   Google Scholar
• CLARK WM, ALBERS GW, MADDEN KP, HAMILTON S: The rtPA (alteplase) 0- to 6-hour acute stroke trial, part A (A0276g): results of a double-blind, placebo-controlled, multicenter study. Thromblytic therapy in acute ischemic stroke study investigators. Stroke (2000) 31(4):811-816.
   PubMed Web of Science ®Google Scholar
• DONNAN GA, DAVIS SM, BLADIN C et al.: Australian Urokinase Stroke Trial (AUST). Stroke (1998) 29(2):550.
   Google Scholar
• DONNAN GA, DAVIS SM, BLADIN C et al.: Australian Urokinase Stroke Trial (AUST). Stroke (2000) 31(10):2536.
   PubMedGoogle Scholar
• DONNAN GA, DAVIS SM, CHAMBERS BR et al.: Streptokinase for acute ischemic stroke with relationship to time of administration: Australian Streptokinase (ASK) Trial Study Group. JAMA (1996) 276(12):961-966.
   PubMed Web of Science ®Google Scholar
• DEL ZOPPO GJ, HIGASHIDA RT, FURLAN AJ, PESSIN MS, ROWLEY HA, GENT M: PROACT: a Phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. PROACT Investigators. Prolyse in Acute Cerebral Thromboembolism. Stroke (1998) 29(1):4-11.
   PubMed Web of Science ®Google Scholar
• MACLEOD MR, DAVIS SM, MITCHELL PJ et al.: Results of a multicentre, randomised controlled trial of intra-arterial urokinase in the treatment of acute posterior circulation ischaemic stroke. Cerebrovasc. Dis. (2005) 20(1):12-17.
   PubMed Web of Science ®Google Scholar
• GROTTA JC, ALEXANDROV AV, tPA-associated reperfusion after acute stroke demonstrated by SPECT. Stroke (1998) 29(2):429-432.
   PubMed Web of Science ®Google Scholar
• HACKE W, BROTT T, CAPLAN L et al.: Thrombolysis in acute ischemic stroke: controlled trials and clinical experience. Neurology (1999) 53(7):S3-S14.
   PubMed Web of Science ®Google Scholar
• HACKE W, KASTE M, FIESCHI C et al.: Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA (1995) 274(13):1017-1025.
   PubMed Web of Science ®Google Scholar
• MARLER JR, TILLEY BC, LU M et al.: Early stroke treatment associated with better outcome: the NINDS rt-PA stroke study. Neurology (2000) 55(11):1649-1655.
   PubMed Web of Science ®Google Scholar
• OIKAWA K, KAMIMURA H, WATANABE T, MIYAMOTO I, HIGUCHI S: Pharmacokinetic properties of a novel tissue-type plasminogen activator pamiteplase after single intravenous administration to rats, dogs, and monkeys. Thromb. Res. (2001) 101(6):493-500.
   PubMed Web of Science ®Google Scholar
• ROSS AM: New plasminogen activators: a clinical review. Clin. Cardiol. (1999) 22(3):165-171.
   PubMed Web of Science ®Google Scholar
• WARDLAW JM, DEL ZOPPO GJ, YAMAGUCHI T: Thrombolysis for acute ischaemic stroke (Cochrane review). Cochrane Database Syst. Rev. (2000)3:CD000213.
   Google Scholar
• WARDLAW JM, LINDLEY RI, LEWIS S: Thrombolysis for acute ischemic stroke: still a treatment for the few by the few. West J. Med. (2002) 176(3):198-199.
   PubMedGoogle Scholar
• WARDLAW JM, WARLOW CP, COUNSELL C: Systematic review of evidence on thrombolytic therapy for acute ischaemic stroke. Lancet (1997) 350(9078):607-614.
   PubMed Web of Science ®Google Scholar
• ZIVIN JA: Thrombolytic stroke therapy: past, present, and future. Neurology (1999) 53(1):14-19.
   PubMed Web of Science ®Google Scholar
• KOSTIS JB, DOCKENS RC, THADANI U et al.: Comparison of pharmacokinetics of lanoteplase and alteplase during acute myocardial infarction. Clin. Pharmacokinet. (2002) 41(6):445-452.
   PubMed Web of Science ®Google Scholar
• ALBERTS MJ: Hyperacute stroke therapy with tissue plasminogen activator. Am. J. Cardiol. (1997) 80(4C):29D-34D; discussion 35D-39D.
   PubMed Web of Science ®Google Scholar
• CANNON CP, GIBSON CM, MCCABE CH et al.: TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: results of the TIMI 10B trial. Thrombolysis in Myocardial Infarction (TIMI) 10B Investigators. Circulation (1998) 98(25):2805-2814.
   PubMed Web of Science ®Google Scholar
• CANNON CP, MCCABE CH, GIBSON CM et al.: TNK-tissue plasminogen activator in acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) 10A dose- ranging trial. Circulation (1997) 95(2):351-356.
   PubMed Web of Science ®Google Scholar
• DAVYDOV L, CHENG JW: Tenecteplase: a review. Clin. Ther. (2001) 23(7):982-997; discussion 981.
   PubMed Web of Science ®Google Scholar
• HACKE W, KASTE M, FIESCHI C et al.: Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet (1998) 352(9136):1245-1251.
   PubMed Web of Science ®Google Scholar
• GERSH BJ: Acute myocardial infarction. Results of the ASSENT-3 Trial. Rev. Cardiovasc. Med. (2002) 3(2):111-115.
   PubMedGoogle Scholar
• SINNAEVE P, ALEXANDER J, BELMANS A et al.: One-year follow-up of the ASSENT-2 trial: a double-blind, randomized comparison of single-bolus tenecteplase and front-loaded alteplase in 16,949 patients with ST-elevation acute myocardial infarction. Am. Heart J. (2003) 146(1):27-32.
   PubMed Web of Science ®Google Scholar
• VAN DE WERF F: ASSENT-3: implications for future trial design and clinical practice. Eur. Heart J. (2002) 23(12):911-912.
   PubMed Web of Science ®Google Scholar
• VAN DE WERF F, ADGEY J, ARDISSINO D et al.: Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Lancet (1999) 354(9180):716-722.
   PubMed Web of Science ®Google Scholar
• LAPCHAK PA, ARAUJO DM, ZIVIN JA: Comparison of tenecteplase with alteplase on clinical rating scores following small clot embolic strokes in rabbits. Exp. Neurol. (2004) 185(1):154-159.
   PubMed Web of Science ®Google Scholar
• LAPCHAK PA, SONG D, WEI J, ZIVIN JA: Coadministration of NXY-059 and tenecteplase six hours following embolic strokes in rabbits improves clinical rating scores. Exp. Neurol. (2004) 188(2):279-285.
   PubMed Web of Science ®Google Scholar
• ZHANG RL, ZHANG L, JIANG Q, ZHANG ZG, GOUSSEV A, CHOPP M: Postischemic intracarotid treatment with TNK-tPA reduces infarct volume and improves neurological deficits in embolic stroke in the unanesthetized rat. Brain Res. (2000) 878(1-2):64-71.
   PubMed Web of Science ®Google Scholar
• HALEY EC Jr, LYDEN PD, JOHNSTON KC, HEMMEN TM: A pilot dose-escalation safety study of tenecteplase in acute ischemic stroke. Stroke (2005) 36(3):607-612.
   PubMed Web of Science ®Google Scholar
• CHAPMAN DF, LYDEN P, LAPCHAK PA, NUNEZ S, THIBODEAUX H, ZIVIN J: Comparison of TNK with wild-type tissue plasminogen activator in a rabbit embolic stroke model. Stroke (2001) 32(3):748-752.
   PubMed Web of Science ®Google Scholar
• MURAMATSU H, IGARASHI H, OKUBO S, KATAYAMA Y: Monteplase reduces infarct volume and hemorrhagic transformation in rat model of embolic stroke. Neurol. Res. (2002) 24(3):311-316.
   PubMed Web of Science ®Google Scholar
• BRINGMANN P, GRUBER D, LIESE A et al.: Structural features mediating fibrin selectivity of vampire bat plasminogen activators. J. Biol. Chem. (1995) 270(43):25596-25603.
   PubMed Web of Science ®Google Scholar
• DEBENS T: Technology evaluation: desmoteplase, PAION/Forest. Curr. Opin. Mol. Ther. (2004) 6(5):567-575.
   PubMed Web of Science ®Google Scholar
• FURLAN AJ, EYDING D, ALBERS GW et al.: Dose Escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS): evidence of safety and efficacy 3 to 9 hours after stroke onset. Stroke (2006) 37(5):1227-1231.
   PubMed Web of Science ®Google Scholar
• GRANDJEAN C, MCMULLEN PC, NEWSCHWANDER G: Vampire bats yield potent clot buster for ischemic stroke. J. Cardiovasc. Nurs. (2004) 19(6):417-420.
   PubMedGoogle Scholar
• HACKE W, ALBERS G, AL-RAWI Y et al.: The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a Phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke (2005) 36(1):66-73.
   PubMed Web of Science ®Google Scholar
• LIBERATORE GT, SAMSON A, BLADIN C, SCHLEUNING WD, MEDCALF RL: Vampire bat salivary plasminogen activator (desmoteplase): a unique fibrinolytic enzyme that does not promote neurodegeneration. Stroke (2003) 34(2):537-543.
   PubMed Web of Science ®Google Scholar
• PETRI T, LANGER G, BRINGMANN P et al.: Production of vampire bat plasminogen activator DSPA α 1 in CHO and insect cells. J. Biotechnol. (1995) 39(1):75-83.
   PubMed Web of Science ®Google Scholar
• REDDROP C, MOLDRICH RX, BEART PM et al.: Vampire bat salivary plasminogen activator (desmoteplase) inhibits tissue-type plasminogen activator-induced potentiation of excitotoxic injury. Stroke (2005) 36(6):1241-1246.
   PubMed Web of Science ®Google Scholar
• SAKHAROV DV, BARRERTT-BERGSHOEFF M, HEKKENBERG RT, RIJKEN DC: Fibrin-specificity of a plasminogen activator affects the efficiency of fibrinolysis and responsiveness to ultrasound: comparison of nine plasminogen activators in vitro. Thromb. Haemost. (1999) 81(4):605-612.
   PubMed Web of Science ®Google Scholar
• SCHIERMEYER A, SCHINKEL H, APEL S, FISCHER R, SCHILLBERG S: Production of desmodus rotundus salivary plasminogen activator α1 (DSPAα1) in tobacco is hampered by proteolysis. Biotechnol. Bioeng. (2005) 89(7):848-858.
   PubMed Web of Science ®Google Scholar
• SCHLEUNING WD: Vampire bat plasminogen activator DSPA-α-1 (desmoteplase): a thrombolytic drug optimized by natural selection. Haemostasis (2001) 31(3):118-122.
   PubMedGoogle Scholar
• TOSCHI L, BRINGMANN P, PETRI T, DONNER P, SCHLEUNING WD: Fibrin selectivity of the isolated protease domains of tissue-type and vampire bat salivary gland plasminogen activators. Eur. J. Biochem. (1998) 252(1):108-112.
   PubMedGoogle Scholar
• COLLEN D: Revival of plasmin as a therapeutic agent? Thromb. Haemost. (2001) 86(3):731-732.
   PubMed Web of Science ®Google Scholar
• LAPCHAK PA, ARAUJO DM, PAKOLA S, SONG D, WEI J, ZIVIN J: Microplasmin: a novel thrombolytic that improves behavioral outcome after embolic strokes in rabbits. Stroke (2002) 33:2279-2284.
   PubMed Web of Science ®Google Scholar
• LAPCHAK PA, ARAUJO DM, SONG D, WEI J, ZIVIN JA: Neuroprotective effects of the spin trap agent disodium-[(tert- butylimino)methyl]benzene-1,3-disulfonate N-oxide (generic NXY-059) in a rabbit small clot embolic stroke model: combination studies with the thrombolytic tissue plasminogen activator. Stroke (2002) 33(5):1411-1415.
   PubMed Web of Science ®Google Scholar
• CHERUBINI A, RUGGIERO C, POLIDORI MC, MECOCCI P: Potential markers of oxidative stress in stroke. Free Radic. Biol. Med. (2005) 39(7):841-852.
   PubMed Web of Science ®Google Scholar
• LOVE S: Oxidative stress in brain ischemia. Brain Pathol. (1999) 9(1):119-131.
   PubMed Web of Science ®Google Scholar
• LAPCHAK PA: NXY-059. Centaur. Curr. Opin. Investig. Drugs (2002) 3(12):1758-1762.
   PubMedGoogle Scholar
• LAPCHAK PA, ARAUJO DM: Spin trap agents: a new approach to stroke therapy. Drug News Perspect. (2002) 15(4):220-225.
   PubMed Web of Science ®Google Scholar
• LAPCHAK PA, ARAUJO DM: Reducing bleeding complications after thrombolytic therapy for stroke: clinical potential of metalloproteinase inhibitors and spin trap agents. CNS Drugs (2001) 15(11):819-829.
   PubMed Web of Science ®Google Scholar
• LAPCHAK PA, ARAUJO DM: Development of the nitrone-based spin trap agent NXY-059 to treat acute ischemic stroke. CNS Drug Rev. (2003) 9(3):253-262.
   PubMedGoogle Scholar
• MAPLES KR, MA F, ZHANG YK: Comparison of the radical trapping ability of PBN, S-PPBN and NXY-059. Free Radic. Res. (2001) 34(4):417-426.
   PubMed Web of Science ®Google Scholar
• CHAMULITRAT W, JORDAN SJ, MASON RP, SAITO K, CUTLER RG: Nitric oxide formation during light-induced decomposition of phenyl N-tert-butylnitrone. J. Biol. Chem. (1993) 268(16):11520-11527.
   PubMed Web of Science ®Google Scholar
• LEES KR, BARER D, FORD GA et al.: Tolerability of NXY-059 at higher target concentrations in patients with acute stroke. Stroke (2003) 34(2):482-487.
   PubMed Web of Science ®Google Scholar
• LEES KR, SHARMA AK, BARER D et al.: Tolerability and pharmacokinetics of the nitrone NXY-059 in patients with acute stroke. Stroke (2001) 32(3):675-680.
   PubMed Web of Science ®Google Scholar
• LEES KR, ZIVIN JA, ASHWOOD T at al.: NXY-059 for acute ischemic stroke. N. Engl. J. Med. (2006) 354(6):588-600.
   PubMed Web of Science ®Google Scholar
• LAPCHAK PA: 3α-OL-5-β-pregnan-20-one hemisuccinate, a steroidal low-affinity NMDA receptor antagonist improves clinical rating scores in a rabbit multiple infarct ischemia model: synergism with tissue plasminogen activator. Exp. Neurol. (2006) 197(2):531-537.
   PubMed Web of Science ®Google Scholar
• HOYTE L, KAUR J, BUCHAN AM: Lost in translation: taking neuroprotection from animal models to clinical trials. Exp. Neurol. (2004) 188(2):200-204.
   PubMed Web of Science ®Google Scholar
• LAPCHAK PA, ZIVIN JA: Ebselen, a seleno-organic antioxidant, is neuroprotective after embolic strokes in rabbits: synergism with low-dose tissue plasminogen activator. Stroke (2003) 34(8):2013-2018.
   PubMed Web of Science ®Google Scholar
• LAPCHAK PA, ARAUJO DM, SONG D, WEI J, ZIVIN JA: Neuroprotective effects of the spin trap agent disodium- [(tert-butylimino)methyl]benzene-1,3- disulfonate N-oxide (generic NXY-059) in a rabbit small clot embolic stroke model: combination studies with the thrombolytic tissue plasminogen activator. Stroke (2002) 33(5):1411-1415.
   PubMed Web of Science ®Google Scholar
• LAPCHAK PA, CHAPMAN DF, ZIVIN JA: Pharmacological effects of the spin trap agents N-t-butyl-phenylnitrone (PBN) and 2,2,6, 6-tetramethylpiperidine- N-oxyl (TEMPO) in a rabbit thromboembolic stroke model: combination studies with the thrombolytic tissue plasminogen activator. Stroke (2001) 32(1):147-153.
   PubMed Web of Science ®Google Scholar
• LAPCHAK PA, CHAPMAN DF, ZIVIN JA: Metalloproteinase inhibition reduces thrombolytic (tissue plasminogen activator)-induced hemorrhage after thromboembolic stroke. Stroke (2000) 31(12):3034-3040.
   PubMed Web of Science ®Google Scholar
• KOTAKE Y: Pharmacologic properties of phenyl N-tert-butylnitrone. Antioxid. Redox Signal. (1999) 1(4):481-499.
   PubMed Web of Science ®Google Scholar
• KURODA S, KATSURA K, HILLERED L, BATES TE, SIESJO BK: Delayed treatment with α-phenyl-N-tert-butyl nitrone (PBN) attenuates secondary mitochondrial dysfunction after transient focal cerebral ischemia in the rat. Neurobiol. Dis. (1996) 3(2):149-157.
   PubMed Web of Science ®Google Scholar
• KURODA S, TSUCHIDATE R, SMITH ML, MAPLES KR, SIESJO BK: Neuroprotective effects of a novel nitrone, NXY-059, after transient focal cerebral ischemia in the rat. J. Cereb. Blood Flow Metab. (1999) 19(7):778-787.
   PubMed Web of Science ®Google Scholar
• MARSHALL JW, DUFFIN KJ, GREEN AR, RIDLEY RM: NXY-059, a free radical-trapping agent, substantially lessens the functional disability resulting from cerebral ischemia in a primate species. Stroke (2001) 32(1):190-198.
   PubMed Web of Science ®Google Scholar
• SYDSERFF SG, BORELLI AR, GREEN AR, CROSS AJ: Effect of NXY-059 on infarct volume after transient or permanent middle cerebral artery occlusion in the rat; studies on dose, plasma concentration and therapeutic time window. Br. J. Pharmacol. (2002) 135(1):103-112.
   PubMed Web of Science ®Google Scholar
• DEHOUCK MP, CECCHELLI R, RICHARD GREEN A, RENFTEL M, LUNDQUIST S: In vitro blood-brain barrier permeability and cerebral endothelial cell uptake of the neuroprotective nitrone compound NXY-059 in normoxic, hypoxic and ischemic conditions. Brain Res. (2002) 955(1-2):229-235.
   PubMed Web of Science ®Google Scholar
• LAPCHAK PA, ARAUJO DM, SONG D, WEI J, PURDY R, ZIVIN JA: Effects of the spin trap agent disodium-[tert- butylimino)methyl]benzene-1,3-disulfonate N-oxide (generic NXY-059) on intracerebral hemorrhage in a rabbit large clot embolic stroke model: combination studies with tissue plasminogen activator. Stroke (2002) 33(6):1665-1670.
   PubMed Web of Science ®Google Scholar
• HERIN GA, DU S, AIZENMAN E: The neuroprotective agent ebselen modifies NMDA receptor function via the redox modulatory site. J. Neurochem. (2001) 78(6):1307-1314.
   PubMed Web of Science ®Google Scholar
• IMAI H, MASAYASU H, DEWAR D, GRAHAM DI, MACRAE IM: Ebselen protects both gray and white matter in a rodent model of focal cerebral ischemia. Stroke (2001) 32(9):2149-2154.
   PubMed Web of Science ®Google Scholar
• PARNHAM M, SIES H: Ebselen: prospective therapy for cerebral ischaemia. Expert Opin. Investig. Drugs (2000) 9(3):607-619.
   PubMed Web of Science ®Google Scholar
• YAMAGUCHI T, SANO K, TAKAKURA K et al.: Ebselen in acute ischemic stroke: a placebo-controlled, double-blind clinical trial. Ebselen Study Group. Stroke (1998) 29(1):12-17.
   PubMed Web of Science ®Google Scholar
• OGAWA A, YOSHIMOTO T, KIKUCHI H et al.: Ebselen in acute middle cerebral artery occlusion: a placebo-controlled, double-blind clinical trial. Cerebrovasc. Dis. (1999) 9(2):112-118.
   PubMed Web of Science ®Google Scholar
• BECKER DA, LEY JJ, ECHEGOYEN L, ALVARADO R: Stilbazulenyl nitrone (STAZN): a nitronyl-substituted hydrocarbon with the potency of classical phenolic chain-breaking antioxidants. J. Am. Chem. Soc. (2002) 124(17):4678-4684.
   PubMed Web of Science ®Google Scholar
• BELAYEV L, BECKER DA, ALONSO OF et al.: Stilbazulenyl nitrone, a novel azulenyl nitrone antioxidant: improved neurological deficit and reduced contusion size after traumatic brain injury in rats. J. Neurosurg. (2002) 96(6):1077-1083.
   PubMed Web of Science ®Google Scholar
• GINSBERG MD, BECKER DA, BUSTO R et al.: Stilbazulenyl nitrone, a novel antioxidant, is highly neuroprotective in focal ischemia. Ann. Neurol. (2003) 54(3):330-342.
   PubMed Web of Science ®Google Scholar
• LEY JJ, VIGDORCHIK A, BELAYEV L at al.: Stilbazulenyl nitrone, a second-generation azulenyl nitrone antioxidant, confers enduring neuroprotection in experimental focal cerebral ischemia in the rat: neurobehavior, histopathology, and pharmacokinetics. J. Pharmacol. Exp. Ther. (2005) 313(3):1090-1100.
   PubMed Web of Science ®Google Scholar
• MOJUMDAR SC, BECKER DA, DILABIO GA, LEY JJ, BARCLAY LR, INGOLD KU: Kinetic studies on stilbazulenyl-bis-nitrone (STAZN), a nonphenolic chain-breaking antioxidant in solution, micelles, and lipid membranes. J. Org. Chem. (2004) 69(9):2929-2936.
   PubMed Web of Science ®Google Scholar
• YANG L, CALINGASAN NY, CHEN J, LEY JJ, BECKER DA, BEAL MF: A novel azulenyl nitrone antioxidant protects against MPTP and 3-nitropropionic acid neurotoxicities. Exp. Neurol. (2005) 191(1):86-93.
   PubMed Web of Science ®Google Scholar
• ROSENBERG GA: Matrix metalloproteinases in brain injury. J. Neurotrauma (1995) 12(5):833-842.
   PubMed Web of Science ®Google Scholar
• MONTANER J, ALVAREZ-SABIN J, MOLINA CA et al.: Matrix metalloproteinase expression is related to hemorrhagic transformation after cardioembolic stroke. Stroke (2001) 32(12):2762-2767.
   PubMed Web of Science ®Google Scholar
• MONTANER J, ALVAREZ-SABIN J, MOLINA C et al.: Matrix metalloproteinase expression after human cardioembolic stroke: temporal profile and relation to neurological impairment. Stroke (2001) 32(8):1759-1766.
   PubMed Web of Science ®Google Scholar
• MONTANER J, MOLINA CA, MONASTERIO J et al.: Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke. Circulation (2003) 107(4):598-603.
   PubMed Web of Science ®Google Scholar
• ABILLEIRA S, MONTANER J, MOLINA CA, MONASTERIO J, CASTILLO J, ALVAREZ-SABIN J: Matrix metalloproteinase-9 concentration after spontaneous intracerebral hemorrhage. J. Neurosurg. (2003) 99(1):65-70.
   PubMed Web of Science ®Google Scholar
• ROSENBERG GA, CUNNINGHAM LA, WALLACE J et al.: Immunohistochemistry of matrix metalloproteinases in reperfusion injury to rat brain: activation of MMP-9 linked to stromelysin-1 and microglia in cell cultures. Brain Res. (2001) 893(1-2):104-112.
   PubMed Web of Science ®Google Scholar
• CHANDLER S, MILLER KM, CLEMENTS JM et al.: Matrix metalloproteinases, tumor necrosis factor and multiple sclerosis: an overview. J. Neuroimmunol. (1997) 72(2):155-161.
   PubMed Web of Science ®Google Scholar
• MUN-BRYCE S, ROSENBERG GA: Matrix metalloproteinases in cerebrovascular disease. J. Cereb. Blood Flow Metab. (1998) 18(11):1163-1172.
   PubMed Web of Science ®Google Scholar
• ROMANIC AM, WHITE RF, ARLETH AJ, OHLSTEIN EH, BARONE FC: Matrix metalloproteinase expression increases after cerebral focal ischemia in rats: inhibition of matrix metalloproteinase-9 reduces infarct size. Stroke (1998) 29(5):1020-1030.
   PubMed Web of Science ®Google Scholar
• LEE SR, TSUJI K, LO EH: Role of matrix metalloproteinases in delayed neuronal damage after transient global cerebral ischemia. J. Neurosci. (2004) 24(3):671-678.
   PubMed Web of Science ®Google Scholar
• ROSENBERG GA, NAVRATIL M: Metalloproteinase inhibition blocks edema in intracerebral hemorrhage in the rat. Neurology (1997) 48(4):921-926.
   PubMed Web of Science ®Google Scholar
• JEAN WC, SPELLMAN SR, NUSSBAUM ES, LOW WC: Reperfusion injury after focal cerebral ischemia: the role of inflammation and the therapeutic horizon. Neurosurgery (1998) 43(6):1382-1396; discussion 1396-1397.
   PubMed Web of Science ®Google Scholar
• ZHANG RL, ZHANG ZG, CHOPP M: Increased therapeutic efficacy with rt-PA and anti-CD18 antibody treatment of stroke in the rat. Neurology (1999) 52(2):273-279.
   PubMed Web of Science ®Google Scholar
• ZHANG L, ZHANG ZG, ZHANG RL, LU M, KRAMS M, CHOPP M: Effects of a selective CD11b/CD18 antagonist and recombinant human tissue plasminogen activator treatment alone and in combination in a rat embolic model of stroke. Stroke (2003) 34(7):1790-1795.
   PubMed Web of Science ®Google Scholar
• LECLERC JR: Platelet glycoprotein IIb/IIIa antagonists: lessons learned from clinical trials and future directions. Crit. Care Med. (2002) 30(Suppl. 5):S332-S340.
   PubMed Web of Science ®Google Scholar
• KRAMS M, LEES KR, HACKE W, GRIEVE AP, ORGOGOZO JM, FORD GA: Acute Stroke Therapy by Inhibition of Neutrophils (ASTIN): an adaptive dose-response study of UK-279,276 in acute ischemic stroke. Stroke (2003) 34(11):2543-2548.
   PubMed Web of Science ®Google Scholar
• ZHANG L, ZHANG ZG, LIU X et al.: Treatment of embolic stroke in rats with bortezomib and recombinant human tissue plasminogen activator. Thromb. Haemost. (2006) 95(1):166-173.
   PubMed Web of Science ®Google Scholar
• ZHANG L, ZHANG ZG, ZHANG RL at al.: Postischemic (6-hour) treatment with recombinant human tissue plasminogen activator and proteasome inhibitor PS-519 reduces infarction in a rat model of embolic focal cerebral ischemia. Stroke (2001) 32(12):2926-2931.
   PubMed Web of Science ®Google Scholar
• TEPE G, SCHOTT U, ERLEY CM et al.: Platelet glycoprotein IIb/IIIa receptor antagonist used in conjunction with thrombolysis for peripheral arterial thrombosis. Am. J. Roentgenol. (1999) 172(5):1343-1346.
   PubMed Web of Science ®Google Scholar
• THOMAS S: Platelet membrane glycoproteins in haemostasis. Clin. Lab. (2002) 48(5-6):247-262.
   PubMedGoogle Scholar
• KURABAYASHI H, TAMURA J, NARUSE T, KUBOTA K: Possible existence of platelet activation before the onset of cerebral infarction. Atherosclerosis (2000) 153(1):203-207.
   PubMed Web of Science ®Google Scholar
• CATELLA-LAWSON F: Vascular biology of thrombosis: platelet–vessel wall interactions and aspirin effects. Neurology (2001) 57(5 Suppl. 2):S5-S7.
   PubMed Web of Science ®Google Scholar
• CATELLA-LAWSON F, KAPOOR S, MORETTI D et al.: Oral glycoprotein IIb/IIIa antagonism in patients with coronary artery disease. Am. J. Cardiol. (2001) 88(3):236-242.
   PubMed Web of Science ®Google Scholar
• CROFFORD LJ, OATES JC, MCCUNE WJ et al.: Thrombosis in patients with connective tissue diseases treated with specific cyclooxygenase 2 inhibitors. A report of four cases. Arthritis Rheum. (2000) 43(8):1891-1896.
   PubMed Web of Science ®Google Scholar
• BELAYEV L, KHOUTOROVA L, DEISHER TA et al.: Neuroprotective effect of SolCD39, a novel platelet aggregation inhibitor, on transient middle cerebral artery occlusion in rats. Stroke (2003) 34(3):758-763.
   PubMed Web of Science ®Google Scholar
• ZHANG ZG, ZHANG L, TSANG W at al.: Dynamic platelet accumulation at the site of the occluded middle cerebral artery and in downstream microvessels is associated with loss of microvascular integrity after embolic middle cerebral artery occlusion. Brain Res. (2001) 912(2):181-194.
   PubMed Web of Science ®Google Scholar
• SHUAIB A, YANG Y, NAKADA MT, LI Q, YANG T: Glycoprotein IIb/IIIa antagonist, murine 7E3 F(ab′) 2, and tissue plasminogen activator in focal ischemia: evaluation of efficacy and risk of hemorrhage with combination therapy. J. Cereb. Blood Flow Metab. (2002) 22(2):215-222.
   PubMed Web of Science ®Google Scholar
• LAPCHAK PA, ARAUJO DM: Therapeutic potential of platelet glycoprotein IIb/IIIa receptor antagonists in the management of ischemic stroke. Am. J. Cardiovasc. Drugs (2003) 3(2):87-94.
   PubMedGoogle Scholar
• LAPCHAK PA, ARAUJO DM, SONG D, ZIVIN JA: The nonpeptide glycoprotein IIb/IIIa platelet receptor antagonist SM- 20302 reduces tissue plasminogen activator-induced intracerebral hemorrhage after thromboembolic stroke. Stroke (2002) 33(1):147-152.
   PubMed Web of Science ®Google Scholar
• BELLANDI F, MAIOLI M, LEONCINI M, TOSO A, DABIZZI RP: Early abciximab administration in acute myocardial infarction treated with primary coronary intervention. Int. J. Cardiol. (2006) 108(1):36-42.
   PubMed Web of Science ®Google Scholar
• LAVI S, GRUBERG L, KAPELIOVICH M et al.: The impact of GP IIb/IIIa inhibitors during primary percutaneous coronary intervention in acute myocardial infarction patients. J. Invasive Cardiol. (2005) 17(6):296-299.
   PubMedGoogle Scholar
• PETRONIO AS, ROVAI D, MUSUMECI G et al.: Effects of abciximab on microvascular integrity and left ventricular functional recovery in patients with acute infarction treated by primary coronary angioplasty. Eur. Heart J. (2003) 24(1):67-76.
   PubMed Web of Science ®Google Scholar
• WOHRLE J, GREBE OC, NUSSER T at al.: Reduction of major adverse cardiac events with intracoronary compared with intravenous bolus application of abciximab in patients with acute myocardial infarction or unstable angina undergoing coronary angioplasty. Circulation (2003) 107(14):1840-1843.
   PubMed Web of Science ®Google Scholar
• CICCONE A, ABRAHA I, SANTILLI I: Glycoprotein IIb-IIIa inhibitors for acute ischaemic stroke. Cochrane Database Syst. Rev. (2006) 4:CD005208.
   PubMedGoogle Scholar
• RINGLEB PA: Thrombolytics, anticoagulants, and antiplatelet agents. Stroke (2006) 37(2):312-313.
   PubMed Web of Science ®Google Scholar
• VELAT GJ, BURRY MV, ESKIOGLU E, DETTORRE RR, FIRMENT CS, MERICLE RA: The use of abciximab in the treatment of acute cerebral thromboembolic events during neuroendovascular procedures. Surg. Neurol. (2006) 65(4):352-358; discussion 358-359.
   PubMed Web of Science ®Google Scholar
• KWON OK, LEE KJ, HAN MH, OH CW, HAN DH, KOH YC: Intraarterially administered abciximab as an adjuvant thrombolytic therapy: report of three cases. Am. J. Neuroradiol. (2002) 23(3):447-451.
   PubMed Web of Science ®Google Scholar
• ECKERT B, KOCH C, THOMALLA G, ROETHER J, ZEUMER H: Acute basilar artery occlusion treated with combined intravenous abciximab and intra-arterial tissue plasminogen activator: report of 3 cases. Stroke (2002) 33(5):1424-1427.
   PubMed Web of Science ®Google Scholar
• HANKEY GJ: Ongoing and planned trials of antiplatelet therapy in the acute and long-term management of patients with ischaemic brain syndromes: setting a new standard of care. Cerebrovasc. Dis. (2004) 17(Suppl. 3):11-16.
   PubMed Web of Science ®Google Scholar
• RICCI S, LEWIS S, SANDERCOCK P: Previous use of aspirin and baseline stroke severity: an analysis of 17,850 patients in the International Stroke Trial. Stroke (2006) 37(7):1737-1740.
   PubMed Web of Science ®Google Scholar
• TRIVEDI SM, SHANI J, HOLLANDER G: Bleeding complications of platelet glycoprotein IIb/IIIa inhibitor abciximab (ReoPro). J Invasive Cardiol. (2002) 14(7):423-425.
   PubMedGoogle Scholar
• DETABOADA L, ILIC S, LEICHLITER-MARTHA S, ORON U, ORON A, STREETER J: Transcranial application of low-energy laser irradiation improves neurological deficits in rats following acute stroke. Lasers Surg. Med. (2006) 38(1):70-73.
   PubMed Web of Science ®Google Scholar
• ILIC S, LEICHLITER S, STREETER J, ORON A, DETABOADA L, ORON U: Effects of power densities, continuous and pulse frequencies, and number of sessions of low-level laser therapy on intact rat brain. Photomed. Laser Surg. (2006) 24(4):458-466.
   PubMed Web of Science ®Google Scholar
• ORON A, ORON U, CHEN J et al.: Low-level laser therapy applied transcranially to rats after induction of stroke significantly reduces long-term neurological deficits. Stroke (2006) 37(10):2620-2624.
   PubMed Web of Science ®Google Scholar
• AD N, ORON U: Impact of low level laser irradiation on infarct size in the rat following myocardial infarction. Int. J. Cardiol. (2001) 80(2-3):109-116.
   PubMed Web of Science ®Google Scholar
• MIRSKY N, KRISPEL Y, SHOSHANY Y, MALTZ L, ORON U: Promotion of angiogenesis by low energy laser irradiation. Antioxid. Redox Signal. (2002) 4(5):785-790.
   PubMed Web of Science ®Google Scholar
• SHEFER G, PARTRIDGE TA, HESLOP L, GROSS JG, ORON U, HALEVY O: Low-energy laser irradiation promotes the survival and cell cycle entry of skeletal muscle satellite cells. J. Cell Sci. (2002) 115(Part 7):1461-1469.
   PubMed Web of Science ®Google Scholar
• SOMMER AP, ORON U, KAJANDER EO, MESTER AR: Stressed cells survive better with light. J. Proteome Res. (2002) 1(5):475.
   PubMed Web of Science ®Google Scholar
• TUBY H, MALTZ L, ORON U: Modulations of VEGF and iNOS in the rat heart by low level laser therapy are associated with cardioprotection and enhanced angiogenesis. Lasers Surg. Med. (2006) 38(7):682-688.
   PubMed Web of Science ®Google Scholar
• LAPCHAK PA, WEI J, ZIVIN JA: Transcranial infrared laser therapy improves clinical rating scores after embolic strokes in rabbits. Stroke (2004) 35(8):1985-1988.
   PubMed Web of Science ®Google Scholar
• LAMPL Y, ZIVIN JA, FISHER M et al.: Infrared laser therapy for ischemic stroke – a new treatment strategy: results of the NeuorThera Effectiveness and Safety Trial-1 (NEST-1). Stroke (2006) (In Press).
   PubMedGoogle Scholar
• SHERMAN DG, ATKINSON RP, CHIPPENDALE T et al.: Intravenous ancrod for treatment of acute ischemic stroke: the STAT study: a randomized controlled trial. Stroke Treatment with Ancrod Trial. JAMA (2000) 283(18):2395-2403.
   PubMed Web of Science ®Google Scholar
• SHERMAN DG, LEVY DE: Outcomes of ancrod in acute ischemic stroke. JAMA (2000) 284(15):1926-1927.
   PubMedGoogle Scholar
• HENNERICI MG, KAY R, BOGOUSSLAVSKY J, LENZI GL, VERSTRAETE M, ORGOGOZO JM: Intravenous ancrod for acute ischaemic stroke in the European Stroke Treatment with Ancrod Trial: a randomised controlled trial. Lancet (2006) 368(9550):1871-1878.
   PubMed Web of Science ®Google Scholar
• FANTACCI M, BIANCIARDI P, CARETTI A et al.: Carbamylated erythropoietin ameliorates the metabolic stress induced in vivo by severe chronic hypoxia. Proc. Natl. Acad. Sci. USA (2006) 103(46):17531-17536.
   PubMed Web of Science ®Google Scholar
• VILLA P, VAN BEEK J, LARSEN AK at al.: Reduced functional deficits, neuroinflammation, and secondary tissue damage after treatment of stroke by nonerythropoietic erythropoietin derivatives. J. Cereb. Blood Flow Metab. (2006) (In Press).
   PubMedGoogle Scholar
• LAPCHAK PA, SALGADO KF, KIRKEBY A, SAGER TN: Nonerythropoietic carbamylerythropoietin improves clinical rating scores in embolized rabbits following multiple infarct ischemic strokes: a therapeutic window study. Stroke (2007) (In Press).
   Google Scholar
• HAHN SM, LEPINSKI DL, DELUCA AM, MITCHELL JB, PELLMAR TC: Neurophysiological consequences of nitroxide antioxidants. Can. J. Physiol. Pharmacol. (1995) 73(3):399-403.
   PubMed Web of Science ®Google Scholar
• CHEN GM, BRAY TM, JANZEN EG, MCCAY PB: Excretion, metabolism and tissue distribution of a spin trapping agent, α-phenyl-N-tert-butyl-nitrone (PBN) in rats. Free Radic. Res. Commun. (1990) 9(3-6):317-323.
   PubMed Web of Science ®Google Scholar
• BIBIKOVA A, BELKIN V, ORON U: Enhancement of angiogenesis in regenerating gastrocnemius muscle of the toad (Bufo viridis) by low-energy laser irradiation. Anat. Embryol. (Berl.) (1994) 190(6):597-602.
   PubMedGoogle Scholar
• SHEFER G, BARASH I, ORON U, HALEVY O: Low-energy laser irradiation enhances de novo protein synthesis via its effects on translation-regulatory proteins in skeletal muscle myoblasts. Biochim. Biophys. Acta (2003) 1593(2-3):131-139.
   PubMed Web of Science ®Google Scholar
• MANOONKITIWONGSA PS, SCHULTZ RL, WHITTER EF, LYDEN PD: Contraindications of VEGF-based therapeutic angiogenesis: effects on macrophage density and histology of normal and ischemic brains. Vascul. Pharmacol. (2006) 44(5):316-325.
   PubMed Web of Science ®Google Scholar
• YU SW, FRIEDMAN B, CHENG Q, LYDEN PD: Stroke-evoked angiogenesis results in a transient population of microvessels. J. Cereb. Blood Flow Metab. (2006) (In Press).
   Google Scholar
• STIVER SI, TAN X, BROWN LF, HEDLEY-WHYTE ET, DVORAK HF: VEGF-A angiogenesis induces a stable neovasculature in adult murine brain. J. Neuropathol. Exp. Neurol. (2004) 63(8):841-855.
   PubMed Web of Science ®Google Scholar
• ZIVIN JA, FISHER M, DEGIROLAMI U, HEMENWAY CC, STASHAK JA: Tissue plasminogen activator reduces neurological damage after cerebral embolism. Science (1985) 230(4731):1289-1292.
   PubMed Web of Science ®Google Scholar
• ZIVIN JA, LYDEN PD, DEGIROLAMI U et al.: Tissue plasminogen activator. Reduction of neurologic damage after experimental embolic stroke. Arch. Neurol. (1988) 45(4):387-391.
   PubMed Web of Science ®Google Scholar
• GINSBERG MD: The validity of rodent brain-ischemia models is self-evident. Arch. Neurol. (1996) 53(10):1065-1067; discussion 1070.
   PubMed Web of Science ®Google Scholar